Active, not recruitingPhase 3NCT05083182
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
Studying Psoriasis-related juvenile idiopathic arthritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Janssen Research & Development, LLC
- Principal Investigator
- Janssen Research & Development, LLC Clinical TrialJanssen Research & Development, LLC
- Intervention
- Ustekinumab(drug)
- Enrollment
- 50 enrolled
- Eligibility
- 5-17 years · All sexes
- Timeline
- 2022 – 2026
Study locations (30)
- Childrens Hospital Los Angeles, Los Angeles, California, United States
- UCLA, Los Angeles, California, United States
- Harvard Medical School - Boston Children's Hospital, Boston, Massachusetts, United States
- Northwell Health, New York, New York, United States
- Montefiore Medical Center, The Bronx, New York, United States
- University of North Carolina, Chapel Hill, North Carolina, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Legacy Emanuel Medical Center, Portland, Oregon, United States
- University of Utah, Salt Lake City, Utah, United States
- STAT Research S A, Ciudad Autonoma Buenos Aires, Argentina
- Hospital de Ninos de Cordoba, Córdoba, Argentina
- Instituto Medico Platense, La Plata, Argentina
- Instituto Caici, Rosario, Argentina
- Centro Medico Privado de Reumatologia, San Miguel de Tucumán, Argentina
- Aarhus Universitetshospital, Aarhus, Denmark
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05083182 on ClinicalTrials.govOther trials for Psoriasis-related juvenile idiopathic arthritis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06751238Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).Novartis Pharmaceuticals
- RECRUITINGPHASE3NCT06869551A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic ArthritisBristol-Myers Squibb
- RECRUITINGPHASE3NCT06668181An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic ArthritisUCB Biopharma SRL
- RECRUITINGPHASE3NCT06100744A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or AdalimumabAbbVie
- RECRUITINGPHASE3NCT05767047A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic ArthritisAmgen
- RECRUITINGPHASE3NCT04804553Apremilast Pediatric Study in Children With Active Juvenile Psoriatic ArthritisAmgen
- ACTIVE NOT RECRUITINGPHASE3NCT04527380A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic ArthritisEli Lilly and Company
See all trials for Psoriasis-related juvenile idiopathic arthritis →